key: cord-0882621-fr8l1d4r authors: Ring, J. title: Another year in the grip of COVID‐19 with slow recovery date: 2021-11-13 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17765 sha: c16a837f37c7117daecd433389c393a38141e771 doc_id: 882621 cord_uid: fr8l1d4r nan The year 2021, when everybody had hoped COVID would finally be overcome, was still very much under the influence of the pandemic; COVID-19 has not gone. But life is slowly returning, with some face-to-face meetings and personal activities restarting, so to say some 'spring' time of contacts in the middle of autumn. The EADV Congress again was virtual-only event, but it was a big success and most of the participants were highly satisfied; some even found that the virtual format has many advantages. Maybe the future will be hybrid in some way. That we survived the pandemic is the result of excellent modern research, especially in virology and immunology and a very effective vaccination programme. Yet, there are still problems, not so much of the medical or biological kindof course there are safety and efficacy issues to be aware of and consider. The major problems are psychological; there seems to be a new and sometimes excessively aggressive opposition against the vaccination. This is an irrational attitude of mind and not a matter of intelligence. This has already happened in the early history of vaccines and vaccination, when small pox vaccination was put forward in Europe alongside with the victorious troops of Napoleon. It played a role in the resistance of Tyrolian farmers around Andreas Hofer in 1809 fighting the French and Bavarian troops; they were motivated to also fight against the vaccination regarded as a 'devilish' procedure to 'demoralize' people and make men impotent. Today, we hear about the danger of implanted microchips by giant companies trying to rule the world. Some of the vaccination enemies are hiding behind allergies, claiming that the vaccine would endanger their life. This can be a problem, but only in very rare individuals who should be tested for allergies against vaccine ingredients before and managed accordingly. We have dealt with this aspect also in our journal. In the life of our journal, we have seen during the first lockdown in spring 2020 an almost exponential growth of manuscript submissions which returned to a still high plateau of ca. 400 submissions per month and a total of 5500 in 2020. This year 2021, the flow was only marginally lower and we will reach an estimated number of ca. 5000 new submissions again. That means a gigantic workload for the editorial office, the Associated Editors Lidia Rudnicka and Franco Rongioletti, the Section Editors and the reviewers. We want to thank all our reviewers without whom it would not be possible to keep or increase the quality of this journal. In 2021, close to 1500 individuals have helped us and we want to thank them; we cannot mention all their names but those who carried out 3 reviews or more will be mentioned by name in the last page of this issue. At the same time, the journal has grown not only in quantity but also in quality. Our top ten cited papers in 2020 comprise guidelines on atopic dermatitis, androgenetic alopecia and photodynamic therapy, review articles on cutibacterium acne, clinical trials on Secukinumab or other biologics mostly used in psoriasis, position statements for hidradenitis suppurativa and prurigo. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The manuscript submissions came from all over the world: among the top twenty submitting countries, ten are outside Europe. China and Italy are in a close race for number 1. It also implies a very high rejection rate which for originals and short reports is between 90% and 90.5%. This means that also good and very good articles cannot be accepted due to lack of space. This was one of the reasonsamong many othersfor EADV to launch a new sister journal namely the open access sister journal JEADV Clinical Practice (JEACP) which has been officially launched in October 2021 under the leadership of the newly elected Editor-in-Chief Antonio Torrelo from Madrid. All the best for him and a big success for the new journal! In spite of the large number of manuscripts, the turnaround time by editor could be kept at an average of 25 days, two-third of the manuscripts got their decision within one month, for 20% we needed two months, only a small number of manuscripts took longer when the decision became difficult or the topic was so special that it was hard to find an expert reviewer. For the author, it is good to know that the medium number of days from receipt of the manuscript at Wiley's production team to Early View online is only 35 days. So, once you get the decision you can be sure that the world can read your work very soon. And the world is reading our journal. In the last 3 years, the number of downloads has shown a steep increase from ca 500 000 per year to 1.5 million in 2020. This has contributed to the increase in impact factor up to 6.166, the highest in the journal's history. Also, the newly produced EADV's podcast which JEADV collaborate with the EADV School team has been gaining traction. Under the guidance of Jan Gutermuth, at least 3 podcasts are produced per month featuring important articles, interviews with experts or discussions about actual problems of our specialty. So we are thankful that we have survived the pandemic more or less without great damages; the science and the scientific and collegial exchange has remained high in spite of missing congresses and face-to-face contacts. The technology of virtual meetings has greatly improved together with the use of teledermatological features in the daily life of our colleagues. The future will not be boring, and we hope to meet again physically next year at various locations. With this hope, I again want to thank all the members of our editorial board, the associate and section editors and the editorial team with Asao Sarukawa, Secil Umitvar, Lilla Nafradi, Natascia Boni, Galadriel Bonnel and Laurence Zulianello for the tremendous and excellent work they have done this year. We also want to thank the EADV Board of Directors and the Executive Committee with the president Alexander Stratigos for manifold support! We have celebrated 30 years of JEADV last month, let us look forward to a new and successful decade. Now, it is my privilege to wish all the readers a Merry Christmas, a smooth change of the years and a peaceful and happy new year 2022! Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study) Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization -systematic review and recommendations from the HS ALLIANCE working group Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men -short version Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications -actinic keratoses, Bowen's disease and basal cell carcinomas European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo None declared. None.